Logo image of KRYS

KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis

NASDAQ:KRYS - Nasdaq - US5011471027 - Common Stock - Currency: USD

148.17  -1.57 (-1.05%)

After market: 148.17 0 (0%)

Fundamental Rating

6

KRYS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. KRYS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. KRYS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, KRYS could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year KRYS was profitable.
KRYS had a positive operating cash flow in the past year.
In multiple years KRYS reported negative net income over the last 5 years.
KRYS had negative operating cash flow in 4 of the past 5 years.
KRYS Yearly Net Income VS EBIT VS OCF VS FCFKRYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

1.2 Ratios

KRYS's Return On Assets of 11.54% is amongst the best of the industry. KRYS outperforms 94.97% of its industry peers.
The Return On Equity of KRYS (12.59%) is better than 94.79% of its industry peers.
With an excellent Return On Invested Capital value of 11.96%, KRYS belongs to the best of the industry, outperforming 96.05% of the companies in the same industry.
Industry RankSector Rank
ROA 11.54%
ROE 12.59%
ROIC 11.96%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
KRYS Yearly ROA, ROE, ROICKRYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin of KRYS (37.18%) is better than 97.85% of its industry peers.
With an excellent Operating Margin value of 40.05%, KRYS belongs to the best of the industry, outperforming 99.28% of the companies in the same industry.
With an excellent Gross Margin value of 93.20%, KRYS belongs to the best of the industry, outperforming 94.08% of the companies in the same industry.
Industry RankSector Rank
OM 40.05%
PM (TTM) 37.18%
GM 93.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRYS Yearly Profit, Operating, Gross MarginsKRYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), KRYS is creating some value.
Compared to 1 year ago, KRYS has more shares outstanding
KRYS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRYS Yearly Shares OutstandingKRYS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KRYS Yearly Total Debt VS Total AssetsKRYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 30.23 indicates that KRYS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 30.23, KRYS belongs to the top of the industry, outperforming 95.69% of the companies in the same industry.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 30.23
ROIC/WACC1.22
WACC9.79%
KRYS Yearly LT Debt VS Equity VS FCFKRYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

KRYS has a Current Ratio of 9.65. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS's Current ratio of 9.65 is fine compared to the rest of the industry. KRYS outperforms 77.38% of its industry peers.
KRYS has a Quick Ratio of 9.27. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
KRYS has a Quick ratio of 9.27. This is in the better half of the industry: KRYS outperforms 76.12% of its industry peers.
Industry RankSector Rank
Current Ratio 9.65
Quick Ratio 9.27
KRYS Yearly Current Assets VS Current LiabilitesKRYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

KRYS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 358.39%, which is quite impressive.
KRYS shows a strong growth in Revenue. In the last year, the Revenue has grown by 247.51%.
EPS 1Y (TTM)358.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3900%
Revenue 1Y (TTM)247.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%94.88%

3.2 Future

The Earnings Per Share is expected to grow by 56.83% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 34.10% on average over the next years. This is a very strong growth
EPS Next Y100.32%
EPS Next 2Y77.57%
EPS Next 3Y64.33%
EPS Next 5Y56.83%
Revenue Next Year41.56%
Revenue Next 2Y43.84%
Revenue Next 3Y42.19%
Revenue Next 5Y34.1%

3.3 Evolution

KRYS Yearly Revenue VS EstimatesKRYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KRYS Yearly EPS VS EstimatesKRYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 35.62 indicates a quite expensive valuation of KRYS.
Compared to the rest of the industry, the Price/Earnings ratio of KRYS indicates a rather cheap valuation: KRYS is cheaper than 93.72% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. KRYS is valued slightly more expensive when compared to this.
KRYS is valuated correctly with a Price/Forward Earnings ratio of 15.72.
Based on the Price/Forward Earnings ratio, KRYS is valued cheaply inside the industry as 94.25% of the companies are valued more expensively.
KRYS's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 35.62
Fwd PE 15.72
KRYS Price Earnings VS Forward Price EarningsKRYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaper than 94.25% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, KRYS is valued cheaper than 93.54% of the companies in the same industry.
Industry RankSector Rank
P/FCF 33.11
EV/EBITDA 24.22
KRYS Per share dataKRYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
KRYS's earnings are expected to grow with 64.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y77.57%
EPS Next 3Y64.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KRYS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KRYSTAL BIOTECH INC

NASDAQ:KRYS (7/11/2025, 8:00:02 PM)

After market: 148.17 0 (0%)

148.17

-1.57 (-1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners97.99%
Inst Owner Change0%
Ins Owners12.05%
Ins Owner Change-0.3%
Market Cap4.28B
Analysts84.71
Price Target209.3 (41.26%)
Short Float %12.3%
Short Ratio7.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.89%
Min EPS beat(2)-13.89%
Max EPS beat(2)27.68%
EPS beat(4)1
Avg EPS beat(4)0.66%
Min EPS beat(4)-13.89%
Max EPS beat(4)27.68%
EPS beat(8)2
Avg EPS beat(8)-13.88%
EPS beat(12)4
Avg EPS beat(12)-10.34%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)0
Avg Revenue beat(2)-5.71%
Min Revenue beat(2)-10.17%
Max Revenue beat(2)-1.26%
Revenue beat(4)1
Avg Revenue beat(4)-1.72%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)5.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.52%
PT rev (3m)-4.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.95%
EPS NY rev (1m)-2.28%
EPS NY rev (3m)-17.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.51%
Valuation
Industry RankSector Rank
PE 35.62
Fwd PE 15.72
P/S 12.84
P/FCF 33.11
P/OCF 30.92
P/B 4.35
P/tB 4.35
EV/EBITDA 24.22
EPS(TTM)4.16
EY2.81%
EPS(NY)9.43
Fwd EY6.36%
FCF(TTM)4.47
FCFY3.02%
OCF(TTM)4.79
OCFY3.23%
SpS11.54
BVpS34.07
TBVpS34.07
PEG (NY)0.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.54%
ROE 12.59%
ROCE 13.42%
ROIC 11.96%
ROICexc 31.49%
ROICexgc 31.49%
OM 40.05%
PM (TTM) 37.18%
GM 93.2%
FCFM 38.78%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 132.67%
Cap/Sales 2.75%
Interest Coverage 250
Cash Conversion 98.59%
Profit Quality 104.32%
Current Ratio 9.65
Quick Ratio 9.27
Altman-Z 30.23
F-Score7
WACC9.79%
ROIC/WACC1.22
Cap/Depr(3y)534.57%
Cap/Depr(5y)974.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)358.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3900%
EPS Next Y100.32%
EPS Next 2Y77.57%
EPS Next 3Y64.33%
EPS Next 5Y56.83%
Revenue 1Y (TTM)247.51%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%94.88%
Revenue Next Year41.56%
Revenue Next 2Y43.84%
Revenue Next 3Y42.19%
Revenue Next 5Y34.1%
EBIT growth 1Y342.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year214.01%
EBIT Next 3Y79.82%
EBIT Next 5YN/A
FCF growth 1Y184.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y224.51%
OCF growth 3YN/A
OCF growth 5YN/A